Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endocyte's ABX Deal To Serve As Springboard For Radioligand Pipeline

Executive Summary

Company gains worldwide rights to mid-stage therapy 177Lu-PSMA-617, which would compete with Bayer/Algeta's radiopharmaceutical Xofigo in metastatic castration-resistant prostate cancer.

Advertisement

Related Content

Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Confirming Rumors, Novartis Buys AAA To Boost Oncology Business
Deal Watch: Celgene The Latest To Buy Into Nimbus’ Computational Chemistry Approach
Merck/Endocyte Mulling Vintafolide’s Future After Failure In Ovarian Cancer
Opening A Window: Algeta Must Find Xofigo’s Place In The Prostate Cancer Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099593

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel